HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC Rule of 40

The Rule of 40 of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 6, 2026 is 8.02 %. In the previous year, Rule of 40 was 13.77 % — a change of -41.77% (lower).

Rule of 40

8.02 %

YoY

-41.77%

Last updated:

Rule of 40 of HaTay Pharmaceutical JSC is 2024 8.02 % . Rule of 40 of HaTay Pharmaceutical JSC was 2023 13.77 % . It decreases by -41.77% lower compared to the previous year.

The HaTay Pharmaceutical JSC Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2017
28.57 VND
Jan 1, 2018
20.39 VND
Jan 1, 2019
24.56 VND
Jan 1, 2020
3.70 VND
Jan 1, 2021
-15.93 VND
Jan 1, 2022
19.74 VND
Jan 1, 2023
13.77 VND
Jan 1, 2024
8.02 VND
The HaTay Pharmaceutical JSC Rule of 40 history
YEARRule of 40YoY
8.02 %-41.77%
13.77 %-30.24%
19.74 %-223.91%
-15.93 %-530.40%
3.70 %-84.93%
24.56 %+20.46%
20.39 %-28.63%
28.57 %-15.05%
33.63 %+70.48%
19.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

Rule of 40 of HaTay Pharmaceutical JSC is 8.02 % in 2024.

On Eulerpool you can find the complete historical development of Rule of 40 HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — HaTay Pharmaceutical JSC

All Key Metrics — HaTay Pharmaceutical JSC